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Background: Left ventricular hypertrophy (LVH) is an independent cardiovascular risk factor in patients with essential
hypertension. The main objective of this study was to assess the echocardiographic prevalence of left ventricular
hypertrophy in patients with hypertension, its risk factors and effect of antihypertensive drugs on its prevalence.
Methods: A hospital based cross sectional study was conducted on 200 hypertensive patients on treatment in
southwest Ethiopia. A pretested structured questionnaire was used to collect data from participants and their
clinical records. Blood pressure and anthropometric measurements were taken according to recommended
standards. Left ventricular mass was measured by transthoracic echocardiography. Associations between categorical
variables were assessed using chi-square test and odds ratio with 95% confidence interval. Logistic regression
model was done to identify risks factors of LVH. P values of < 0.05 were considered as statistically significant.
Results: The mean age, systolic blood pressure, diastolic blood pressure and body mass index were 55.7 ±
11.3 years, 139.2 ± 7.7 mmHg, 89.2 ± 5.7 mmHg and 24.2 ± 3.4 Kg/m2 respectively. The overall prevalence of LVH
among these study subjects was 52%. Age ≥50 years (OR: 3.49, 95% CI 1.33-9.14, P = 0.011), female gender (OR: 7.69,
95% CI 3.23-20.0, P < 0.001), systolic blood pressure ≥140 mmHg (OR: 2.85, 95% CI 1.27-6.41, P = 0.011), and duration
of hypertension (OR: 3.59, 95% CI 1.47-8.76, P = 0.005) were independent predictors of left ventricular hypertrophy.
Angiotensin converting enzyme (ACE) inhibitors were the only antihypertensive drugs associated with lower risk of
left ventricular hypertrophy (OR: 0.08, 95% CI 0.03-0.19, p < 0.001).
Conclusions: Left ventricular hypertrophy was found to be highly prevalent in hypertensive patients in Ethiopia. ACE
inhibitors were the only antihypertensive drugs associated with reduced risk of LVH. We thus recommend strategies to
early detect and treat hypertension and to timely screen for LVH among patients with hypertension. Multicenter
prospective studies in Africa settings would be ideal to identify the best antihypertensive agents in black Africans.
Keywords: Hypertension, Left ventricular hypertrophy, Cardiovascular disease, Angiotensin converting enzyme
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Cardiovascular disease (CVD) is the leading cause of death
globally resulting in about 30% of deaths annually. About half
of CVD related deaths are attributable to hypertension, a dis-
ease strongly associated with overall cardiovascular risk [1].
Long standing hypertension results in left ventricular
hypertrophy (LVH), a preclinical cardiac damage that in
the long run may lead to potentially life-threatening* Correspondence: esakgd@gmail.com
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stated.complications [2,3]. LVH is strongly associated with major
cardiovascular events [4-11]. Its echocardiographic preva-
lence varies from around 20% to over 70% based on the
criteria used and population studied [4,7,12-14].
Cardiac hypertrophy is a compensatory response to car-
diac insult of any cause [13]. It is the phenotypic conse-
quence of interactions between genetic and non-genetic
factors that involve multiple etiologies and complex mecha-
nisms. Genes encoding proteins involved in the structure of
the left ventricle (LV) and genes encoding cell signal trans-
duction, hormones, growth factors, calcium homeostasis,td. This is an Open Access article distributed under the terms of the Creative
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ment of LVH [15]. However, identification of specific gen-
etic and molecular mechanisms for LVH in hypertensive
patients is challenging [15-17]. For instance, CaMK4 gene
deletion in mice was found to be linked with occurrence of
hypertension, resultant LVH and reduced survival. How-
ever, treatment with furosemide in such mice prevented the
development of both hypertension and LVH suggesting that
LVH is a result of increased BP rather than being genetic-
ally determined [16].
Despite these challenges, the pathophysiologic mecha-
nisms of LVH appear to be well established now. LVH is
a myocardial remodeling [13] that ensues through acti-
vation of different signaling pathways [15] which involve
mechanical [18] and neurohormonal activation by agents
such as catecholamines and vasoactive peptides (angio-
tensin II or the endothelins) [19,20]. The benefits of
beta-blockers and renin-angiotensin aldosterone system
inhibitors in the treatment of CVDs are thus derived
from their inhibition of these neurohormonal mecha-
nisms [13]. Their importance in heart failure in particu-
lar has recently been elaborated [21].
Secondary messengers that regulate nuclear transcrip-
tion factors activity (NF-κB, CREB, NFAT, and GATA-4)
are activated in response to the neurohormonal activa-
tion. The nuclear transcription factors modify the ex-
pression of hypertrophic genes [22,23]. NF-κB is the
most prominent of these transcription factors that
modulate cellular response in myocardial remodeling
[24]. This was shown by inhibition of NF-κB transcrip-
tion activity by intracardiac injection of AdGRK5-NT
that reduced LVH. Treatment with captopril (angioten-
sin converting enzyme inhibitor) also significantly re-
duces the heart size and inhibits NF-κB activity [25].
Though different mechanisms interplay in the develop-
ment of LVH, there is a consistent and independent inter-
action between hypertension and left ventricular mass
(LVM) [3]. However, the relationship between degree of
hypertension and LVM is not linear. LVH may occur in
patients with borderline hypertension. It is a major risk
factor for coronary artery disease all-cause mortality even
in the absence of symptoms and other cardiovascular risk
factors [26]. The effect is even more prominent in black
patients [27] where it was found to be associated with
greater relative and attributable risk than the traditional
risk factors for coronary disease [28].
Apart from hypertension itself, different factors are be-
lieved to play a role in the development of LVH. Obesity,
dyslipidemia, diabetes mellitus, smoking, old age and exces-
sive alcohol intake are said to be positively correlated with
the prevalence of LVH in hypertensive patients [12,29-32].
Studies regarding LVH and its sequel are scarce in
Black Africans. Most prevalence data for hypertension
and LVH as well as treatment recommendations areextrapolated from the findings in African Americans.
The main aim of the current study is thus to assess the
prevalence of left ventricular hypertrophy in Ethiopian
hypertensive patients and role of ACE inhibitors in pre-
venting LVH in patients with hypertension.
Methods
Settings
This is a cross-sectional study conducted at the Jimma
University Specialized Hospital (JUSH) between May
and August 2012. JUSH is a referral hospital for around
15 million people in southwest Ethiopia. It is one of the
few teaching hospitals in the country. It is located in
Jimma town, 356 km south-west of the capital Addis
Ababa. At the time of the study, there were around 1100
patients on active follow-up for hypertension at hyper-
tension clinic of the hospital. The clinic runs once a
week every Wednesday. The service is rendered by inter-
nists, medical residents and medical interns.
Selection of participants
Hypertensive patients coming for follow-up to the hos-
pital were consecutively recruited based on the selection
criteria and their willingness to participate in the study.
Over a period of four months, complete data from the
patient interview, physical examination, chart review and
echocardiographic assessment was done in 200 hyper-
tensive patients.
Inclusion criteria
Any adult hypertensive patient over 18 years of age com-
ing to the clinic for follow up was enrolled for the study
based on their willingness and consent.
Exclusion criteria
All hypertensive patients with heart failure were ex-
cluded from the study.
Data collection process and instrument
The data were collected using a pre-tested structured
questionnaire which was prepared specifically for this
study. Patient interviews, BP and anthropometric mea-
surements were done by nurses working in the clinic
after one day of training. Chart review was done by
medical residents. The questionnaire consisted of socio-
demographic profiles; physical measurements (blood
pressure, weight, height) and clinical records for co-
morbidities, duration of hypertension and the types of
antihypertensive medications used. Blood pressure was
measured with a sphygmomanometer. An average of
three blood pressure measurements was taken to as-
sess blood pressure control (the current and the last
two visits). Height and weight were measured using a
standard weighing scale and stadiometer respectively.
Table 1 Background Characteristics of hypertensive
patients in Ethiopia
Characteristics
Age (years), Mean ± SD 55.7 ± 11.1






Duration of hypertension, N (%)






SBP (mmHg ), Mean ± SD 139.23 ± 7.79
DBP (mmHg), Mean ± SD 89.24 ± 5.75
BMI (Kg/m2), Mean ± SD 24.22 ± 3.47
BMI (Kg/m2), N (%)
<25 130 (65.0)
25 – 29 56 (28.0)
≥30 14 (7.0)
SBP – systolic blood pressure, DBP – diastolic blood pressure.
BMI – Body mass index.
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straight without shoes and wearing only light clothes.
Transthoracic echocardiography was performed to meas-
ure parameters used to estimate left ventricular mass
(LVM). M-mode tracing was done at the papillary muscle
level of the left ventricle to measure posterior wall thick-
ness in diastole (PWTd), interventricular septal wall thick-
ness in diastole (IVSTd) and left ventricular internal
diameter in diastole (LVIDd). Absolute LVM was calcu-
lated by the Devereux formula given as 0.8 * 1.04 ((PWTd
cm + IVSTd cm + LVIDd cm)3 – LVIDd3cm )) + 0.6 grams
[33]. The LVM was indexed to body surface area (BSA).
LVH was defined as LVM/BSA of > 116 g/m2 for men
and > 96 g/m2 for women [33].
Data analysis
Data were analyzed using SPSS version 20. The findings
were expressed as mean ± standard deviation and/or
percentages. Categorical variables were compared using
Chi-square test and odds ratio with 95% confidence
interval. A P-value of less than 0.05 was considered statis-
tically significant. The logistic regression model was done
to identify predictors/risks of left ventricular hypertrophy.
Ethical considerations
Ethical clearance was obtained from Jimma university
ethical review board. Informed written consent was ob-
tained from every participant. The information collected
from participants will remain confidential indefinitely.
Patients with life threatening conditions were exempted
from the study and were linked for appropriate care.
Results
Background characteristics
A total of 200 hypertensive patients were included in the
study of which 57% were women. The mean age of the
participants was 55.7 ± 11.1 years with a range of 22
to78 years. Hundred forty-nine (74.5%) of them were
older than 50 years. About 70% of them had hyperten-
sion for 10 years or more. The mean systolic blood pres-
sure (SBP) and diastolic blood pressure (DBP) were
139.2 ± 7.7 mmHg and 89.2 ± 5.7 mmHg respectively
(Table 1).
Thirty-nine (19.5%) of patients have been diagnosed
with diabetes and were on glucose lowering agents (in-
sulin or oral glucose lowering agent), 28 of them had
type 2 diabetes.
None of the participants reported smoking or use of
alcohol.
The mean Body Mass Index (BMI) was 24.2 ± 3.4 Kg/m2.
Fifty-six (28%) of them were found to be overweight and
14 patients (7%) were classified as obese according to the
standard classification of overweight as BMI ≥25 Kg/m2
and obesity as BMI ≥30 kg/m2 (Table 1).Treatment of hypertension
All of the participants were taking some types of antihy-
pertensive agents at the time of the study. About 57% of
them were taking a combination of two or more antihy-
pertensive drugs. The most commonly used drug was
hydrochlorothiazide used in 53% of the participants as
the only agent or in combination with others. About
42% of them were taking angiotensin converting enzyme
(ACE) inhibitors alone or in combination with others.
Beta-blocker (atenolol) alone or in combination with
other agents was used by 38% of the participants. None
of the patients were taking angiotensin receptor blockers
(ARB) (Table 2).
Echocardiographic findings and the Prevalence of left
ventricular hypertrophy
The mean posterior wall thickness in diastole (PWTd),
interventricular septal wall thickness in diastole (IVSTd)
and left ventricular internal diameter in diastole (LVIDd)
were 1.28 ± 0.25, 1.38 ± 0.31and 3.93 ± 0.4 centimeters
respectively. The mean calculated left ventricular mass
from the three parameters according to the Devereux
formula was 193.4 ± 60.6 grams. When indexed to BSA,
it was 107.3 ± 33.6 g/m2.
Table 2 Types of anti-hypertensive drugs used by
hypertensive patients in Ethiopia, August 2012
Types of anti-hypertension drug N %
Thiazide diuretic only 40 20.0
ACE inhibitor only 32 16.0
Beta blocker only 15 7.5
ACE inhibitor + Thiazide diuretic 18 9.0
Beta blocker + Thiazide diuretic 23 11.5
Calcium channel blocker + Thiazide diuretic 7 3.5
ACE inhibitor + Beta blocker 11 5.5
ACE inhibitor + Calcium channel blocker 4 2.0
Calcium channel blocker + Beta blocker 3 1.5
Three drugs (different combinations) 47 23.5
Table 3 Bivariate analysis of risk factors for Left
ventricular Hypertrophy among hypertensive patients in
Ethiopia
Predictor variables LVH ( N = 200 ) P-value
Yes, N (%) No, N (%)
Sex Female 78(68.4) 36(31.6) <0.001
Male 26(30.2) 60(69.8)
Age ≥50 years 92(61.7) 57(38.3) <0.001
<50 years 12(23.5 ) 39(76.5)
BMI ≥25 Kg/m2 40(57.1) 30(42.9) 0.172
<25 Kg/m2 64(49.2) 66(50.8)
SBP ≥140 mmHg 65(63.7) 37(36.3) <0.001
<140 mmHg 39(39.8) 59(60.2)
DBP ≥90 mmHg 56(56.0) 44(44.0) 0.258
<90 mmHg 48(48.0) 52(52.0)
History of DM Yes 20(51.3) 19(48.7) 0.920
No 84(52.2) 77(47.8)
Type of DM Type 2 15(53.6) 13(46.4) 0.897
Type 1 5(45.5) 6(54.5)
ACE inhibitor No 86(74.1) 30(25.9) <0.001
Yes 18(21.4) 66(78.6)
Beta Blocker Yes 43(57.3) 32(42.7) 0.242
No 61(48.8) 64(51.2)
Duration of hypertension ≥10 years 88(62.9) 52(37.1) <0.001
<10 years 16(26.7) 44(73.3)
Thiazide diuretic Yes 54(50.9) 52(49.1) 0.751
No 50(53.2) 44(46.8)
Calcium channel blocker Yes 9(47.4) 10(52.6) 0.671
No 95(52.5) 86(47.5)
DM – diabetes mellitus, ACE – angiotensin converting enzyme.
Table 4 Independent risk factors for Left ventricular
Hypertrophy among hypertensive in Ethiopia
Risk factors Adjusted OR 95% CI for OR P-value
Age 3.49 1.33 9.14 0.011
Sex (female) 7.69 3.23 20.0 <0.001
Systolic BP 2.85 1.27 6.41 0.011
ACE inhibitor 0.08 0.03 0.19 <0.001
Duration of hypertension 3.59 1.47 8.76 0.005
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trophy based on criteria of LMV/BSA >116 g/m2 for
men and >96 g/m2 for women was 52%. There was a sig-
nificant difference in its prevalence between genders,
68.4% among women and 30.2% among men (p < 0.001)
(Table 3).
Risk factors for the development of left ventricular
hypertrophy
Age
Of the 104 patients with left ventricular hypertrophy, 92
(88.4%) were 50 years or older. A bivariate analysis showed
that age ≥50 years was associated with the development
of LVH (crude OR: 5.24 95% CI 2.53- 10.84, P < 0.001)
(Table 3). When age was adjusted for other variables in
logistic regression, it remained an independent risk
factor for the development of LVH (adjusted OR: 3.49,
95% CI 1.33-9.14, P = 0.011) (Table 4).
Gender
The prevalence of LVH in women was found to be
68.4% versus 30.2% in men. Bivariate analysis showed
that females were 5 times more likely to develop LVH as
compared to their male counterparts (crude OR: 5.0,
95% CI 2.72- 9.16, P < 0.001) (Table 3). Controlling for
other potential risk factors on logistic regression, this ef-
fect remains significant (adjusted OR = 7.69(3.23-20.0),
P < 0.001) (Table 4).
BMI
Overall, 70 (35%) of the participants had BMI ≥25 Kg/m2.
However, there was no significant difference in the pro-
portion of LVH between individuals with normal or high
BMI (P = 0.172).
Diabetes mellitus
Diabetes was not found to be a significant predictor of
LVH in this study. All of the 28 type 2 patients weretaking oral glucose lowering agents as all type 1 patients
were on insulin. However, neither the type of diabetes
nor the treatment was associated with LVH.
Degree of blood pressure control
At the time of this study, about 60% of the participants
had high blood pressure defined as SBP ≥ 140 mmHg
and/or DBP ≥ 90 mmHg. Significant difference in preva-
lence of LVH was detected only when dichotomizing the
Jaleta et al. BMC Research Notes 2014, 7:45 Page 5 of 8
http://www.biomedcentral.com/1756-0500/7/45high BP into SBP or DBP. Elevated systolic blood pres-
sure was found to be an independent predictor of LVH
in patients with hypertension, (adjusted OR: 2.85, 95%
CI 1.27–6.41, p = 0.011). However, a significant inter-
action between DBP and LVH was not seen (p = 0.258)
(Tables 3 and 4).
Duration of hypertension
About 70% of the participants reported that they had
hypertension for 10 years or more. The prevalence of
LVH in this group was 62.9% versus 26.7% in those who
were less than 10 years since diagnoses. Adjusting for all
potential risk factors, patients with longstanding hyper-
tension (≥10 years) were 3.59 times more likely to de-
velop LVH as compared to those with less than 10 years
of hypertension (adjusted OR: 3.59, 95% CI 1.47- 8.76,
P = 0.005) (Table 4).
Types of antihypertensive agent used and the risk of LVH
Comparison of LVM index was done among each anti-
hypertensive agent used. Apparently lower LVM was
seen in patients taking ACE inhibitors alone or in com-
bination with other agents at the time of the study. The
findings were comparable among other antihypertensive
agents. Multivariate logistic regression also showed a de-
creased risk of LVH (adjusted OR: 0.08, 95% CI 0.03-
0.19, p < 0.001) for those on ACE inhibitors (Table 4).
ACE inhibitors were used more widely in patients
older than 50 years (66.4%) and in those with diabetes
(82%). These agents were used less often (<50%) in other
groups. The effect of ACE inhibitors on LVH was inde-
pendent of these groupings. However, this effect van-
ished in those with high blood pressure (SBP ≥160).
When we grouped antihypertensive agents to those
with anti-remodeling effect (ACE inhibitors and beta-
blockers) and non-anti-remodeling drugs (other groups),
a positive trend towards anti-remodeling agents was
seen though not statistically significant (adjusted OR:
0.11, 95% CI 0.09-1.02, p < 0.001).
Discussion
Left ventricular hypertrophy, a preclinical cardiac dam-
age, was found to be highly prevalent in Ethiopian
hypertensive patients. Age, female gender, longstanding
and systolic hypertension were found to be independent
predictors for its occurrences. Use of ACE inhibitors was
associated with decreased risk of LVH. This cross-
sectional study from a single health facility in Africa may
give clues to the effect of ACE inhibitors in the treat-
ment of hypertension and their effect on LVH in black
patients.
LVH is an independent cardiovascular risk factor [3].
Its prevalence in hypertensive patients in most litera-
tures worldwide varies from 20 to 70% based on thepopulation studied and the criteria used [7,13,14,34].
The overall prevalence of left ventricular hypertrophy of
52% among hypertensive subjects in our study lies
within this range.
Age was found to be an independent risk factor for
LVH in most studies [7,8,35,36]. The finding in our
study is also consistent with these findings.
Female gender was found to be an independent risk
factor for LVH in hypertensive patients in our study with
adjusted OR of 7.69. Different studies from around the
world have shown that the gender effect on prevalence
of LVH varies from population to population [35-39],
whether ECG or echocardiography is used for its assess-
ment [7] and criteria used [34]. A study in Pakistan, for
instance, revealed that women were 11.35 times more
likely to develop LVH than the male counterparts even
after adjusting for other factors [37]. Similarly, studies in
Nigeria [38], China [12] and the LIFE (losartan interven-
tion for endpoint reduction in hypertension) study [39]
showed a trend towards a higher prevalence in women.
However, some studies from European countries have
shown a higher prevalence in men [35,36]. Whether
these differences are due to population studied or cri-
teria used or cutoff points used need to be addressed in
future studies.
The presences of diabetes [40] and high BMI [8,9]
have shown significant correlations with LVH in most
studies. However, in our study, neither history of dia-
betes nor the type of treatments for hyperglycemia
showed any association with LVH. Our assessments for
diabetes were based on only self-reported diagnosis
without blood glucose test. Besides, the small sample
size might not be enough to see this correlation. Ab-
sence of correlation between LVH and body habitus in
our study can also be explained by the small sample size.
Uncontrolled systolic blood pressure ≥140 mmHg was
associated with the development of left ventricular
hypertrophy in this study. However, no correlation was
found between diastolic blood pressure and the occur-
rence of LVH. These findings are consistent with results
from other studies [41]. The reason for this difference
could be due to the fact that diastolic hypertension is as-
sociated more with diastolic dysfunction than systolic
dysfunction and LVH [41].
Duration of hypertension was found to be an inde-
pendent predictor of left ventricular hypertrophy in our
study which is consistent with most studies from around
the world [42,43].
The fact that all of our study participants were non-
smokers and nonalcoholic was merely a chance occur-
rence. This can also be explained by the fact that the
prevalence of smoking in Ethiopia is low, 3.3% in the
general population and 0.5% for women [44] who made
for the larger part of our study participants. In addition,
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sion for over 10 years and all have been on treatment for
their hypertension, abstinence from smoking for medical
reason may also explain our findings.
As LVH is a cardiac remodeling problem [5,13], we
tried to evaluate the effect of anti-remodeling drugs
(beta-blockers and ACE inhibitors) on the risk of LVH.
It was found that patients using ACE inhibitors at the
time of the study had a lower LVM index and decreased
risk of LVH as compared to other agents. The effect of
beta-blockers was however less pronounced. Evidences
have shown that anti-remodeling agents like beta-blockers,
ACE inhibitors and ARB have protective effect against
development of LVH. Besides, they can even reverse an
established LVH and improve left ventricular function
[45-49]. We understand that such cross-sectional study
like ours may not be enough to see the full effect of
these drugs on regression of LVH.
In addition to this, recent studies have also casted
doubts on the benefits of these drugs among black pa-
tients [50]. Such evidences showed that ACE inhibitors,
ARB and beta-blockers are less effective than calcium
channel blockers and diuretics in black hypertensive pa-
tients with or without LVH due low plasma renin level
in blacks [50,51]. However, most of these studies were
extrapolated from findings in African-Americans. Multi-
center studies in indigenous Africans would be ideal to
identify best antihypertensive drug options in such set-
ting where the dietary habits and physique are so diverse
(for instance, West Africans versus East Africans).
Another explanation for the lack of effect of beta-
blockers in our study may be due to the fact that most
(56%) of the patients on these agents had high SBP
(≥160 mmHg). In these patients, beta-blockers were
used as additional antihypertensive agents after blood
pressure control became difficult with original one or
two types of antihypertensive drugs. It should also be
reminded here that the benefit of beta-blockers on re-
gression of LVH and uncomplicated hypertension is be-
coming questionable [52]. In addition to this, carvedilol
is the beta-blocker of choice in patients with hyperten-
sive LVH [53]. The beta-blocker used in our study was
however atenolol.
The effect of ACE inhibitors on LVH also vanished in
those with SBP ≥ 160 mmHg. This is contrary to the fact
that ACE inhibitors induce left ventricular hypertrophy
regression, independent of changes in blood pressure
[54]. Cross-sectional study like ours may not be enough
to see these effects.
Even though this study has come up with such import-
ant findings, there are important limitations worth men-
tioning here. First of all, the relatively small sample size
might have contributed to the inability to detect the ef-
fect of certain risk factors for LVH. For example none ofthe participants reported a history of smoking or alcohol
use. On the other hand, other potential risk factors for
LVH like dyslipidemia, anemia and renal dysfunction
were not assessed making an assessment of risk factors
incomplete. Finally, as all of the participants were those
on pharmacological treatment for hypertension, it may
not be generalizable for all patients with hypertension in
the country.
Conclusion
Left ventricular hypertrophy was found to be highly
prevalent in Ethiopian hypertensive patients where BP
control is suboptimal. Older age, female gender, long-
standing and systolic hypertension were independent
predictors of LVH. ACE inhibitor use on the other hand
has been associated with lower risk of this complication.
Taking these results and observations into consideration,
we thus recommend early screening of hypertensive pa-
tients for LVH with either echocardiography or electro-
cardiography based on availability. Besides, we urge
health care providers and policymakers to improve stan-
dards of care for hypertensive patients by optimizing BP
control and working on those modifiable risk factors of
LVH.
Last but not least, we recommend a large scale multi-
center study to substantiate the findings in this research.
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